IP Library › Granted Patent US 8,435,960
Granted Patent B2
US 8,435,960 · App. 12/130,405 · Granted May 7, 2013

Devices for improved wound management

Inventors: Roderic M. K. Dale (Wilsonville, OR); Steven L. Gatton (Lake Oswego, OR); Amy Arrow (Bethel, ME)
Assignee: Lakewood-Amedex, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,960
App. No.
12/130,405
Granted
May 7, 2013
Kind
B2
Abstract

The present invention provides devices and compositions for the management of infection of topical lesions, each of the devices and compositions containing protonated/acidified nucleic acids either on its surface, or integrated into the device. These modified nucleic acids are effective as bactericidal and/or bacteriostatic agents without regard to the class of bacteria, so are especially useful when diagnosis is difficult or when multiple infectious organisms are present. The antibiotic activity of nucleic acids of the invention is not dependent on either the specific sequence of the nucleic acid or the length of the nucleic acid molecule. The nucleic acids used in the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about 1, more preferably less than pH 4.5 to about 1, and even more preferably less than pH 2 to about 1.

Claims (5)

1. A method of treating a wound comprising applying to said wound a composition comprising an antibacterial formulation comprising a protonated/acidified nucleic acid of up to 23 nucleotides, wherein said protonated/acidified nucleic acid comprises a backbone structure modified from that of naturally occurring nucleic acids, and wherein said protonated/acidified nucleic acid has a pH of about 1.0 to about 4.0 when dissolved in water, wherein said composition inhibits the growth of pathogenic bacteria in said wound, wherein said pathogenic bacteria is selected from the group consisting of Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Staphylococcus spp., Streptococcus mutans, Escherichia coli , and Klebsiella pneumonia , thereby treating said wound.

2. The method of claim 1 , wherein said protonated/acidified nucleic acid is a monomer.

3. The method of claim 2 , wherein said monomer comprises a blocking chemical modification at the 5′ position of the monomer and a blocking chemical modification at the 3′ position of the monomer.

4. The method of claim 1 , wherein the formulation of said protonated/acidified nucleic acid is from about 0.1 to about 5 percent of the dry weight of the composition.

5. The method of claim 1 , wherein said composition is applied topically, intravenously, or subcutaneously to said wound.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2012
From: OLIGO THERAPEUTICS INC.
To: OLIGOS ETC., INC.
Reel/Frame 028653/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2012
From: DALE, RODERIC M.K.; GATTON, STEVEN L.; ARROW, AMY
To: OLIGOS ETC. INC. AND OLIGO THERAPEUTICS, INC.
Reel/Frame 028647/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2009
From: OLIGOS ETC., INC.
To: LAKEWOOD-AMEDEX, INC.
Reel/Frame 022162/0349 →
Continuity (4)
Continuation 10644969 · Aug 21, 2003
Division 09281858 · Mar 31, 1999
Continuation In Part 09222009 · Dec 30, 1998
Related Publication 20090092659A1 · Apr 9, 2009